<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634373</url>
  </required_header>
  <id_info>
    <org_study_id>PK-08-111</org_study_id>
    <nct_id>NCT01634373</nct_id>
  </id_info>
  <brief_title>Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets</brief_title>
  <official_title>An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus SeroquelÂ® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      Primary objective was to study Steady-state bioequivalence of Torrent's Quetiapine Fumarate
      Tablets 300 mg.

      Study Design:

      Randomized, Two-Way, Crossover, multiple Dose, and Open-Label
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Quetiapine Fumarate Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: Male of female

          -  Age: 25-65 years

          -  Patients who are receiving a stable daily dose of quetiapine 300 mg every 12 hourly
             for atlist one month

          -  Patient willing to adhere to the protocol requirements

        Exclusion Criteria:

          -  Clinically relevant abnormalities in the results of the laboratory screening
             evaluation.

          -  Clinically significant abnormal ECG.

          -  Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm
             Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)

          -  Concurrent use of antihypertensive medication or any medication that might pre-dispose
             to orthostatic hypotension.

          -  History of allergic reactions to quetiapine or other chemically related psychotropic
             drugs.

          -  Concurrent primary psychiatric or neurological diagnosis including organic mental
             disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease.

          -  Existence of any surgical or medical condition, which in the judgement of the
             Principal Investigator, might interfere with the absorption, distribution, metabolism
             or excretion of the drug or likely to compromise the safety of patients.

          -  Concurrent use of other drugs known to suppress bone marrow function.

          -  HIV, HCV, HBsAg positive.

          -  Expected changes in concomitant medications during the period of study.

          -  A history of epilepsy or risk for seizures

          -  positive urine drug of abuse test at enrollment.

          -  A history of alcohol or drug dependence by Diagnostic and statistical manual of Mental
             disorders IV(DSM-IV) criteria during the 6 month period immediately prior to study
             entry.

          -  A total white blood cell count below 4000/ml, or absolute neutrophil count below
             2000/ml

          -  Female patients with pregnancy or Breast feeding or intend to become pregnant during
             the study and not able to follow contraception methods.

          -  History of multiple syncopal episodes.

          -  Administration any study drugs in last 3 months prior to entry in the study.

          -  History of significant blood loss due to any reason in the past 3 months.

          -  Any pre-existing bleeding disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asha Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>July 2, 2012</last_update_submitted>
  <last_update_submitted_qc>July 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

